2023 World Conference on Lung Cancer (Posters)-P1.21. NSCLC Microenvironment Subtypes Correlate with Response and Survival to Immune Checkpoint Inhibitor Therapy

P1.21. NSCLC Microenvironment Subtypes Correlate with Response and Survival to Immune Checkpoint Inhibitor Therapy - PDF(Abstract)

Back to course

Pdf Summary

This abstract discusses a study that aimed to identify biomarkers that can predict response and survival to immune checkpoint inhibitor (ICI) therapy in patients with non-small cell lung cancer (NSCLC). The study used RNA-seq technology to classify the tumor microenvironment (TME) into different subtypes and assessed their correlation with ICI treatment outcomes. The researchers analyzed 75 NSCLC patients who received ICI therapy as their first-line treatment and had no target EGFR mutations or ALK fusions.<br /><br />The results showed that patients with TME subtypes known as immune-enriched (IE) and immune-enriched/fibrotic (IE/F) had superior progression-free survival (PFS) compared to patients with other TME subtypes. The researchers combined the TME subtypes into "hot" (IE and IE/F) and "cold" (desert and fibrotic) groups and found that patients in the hot group had longer PFS than those in the cold group. CD8 T cell infiltration was associated with better PFS in patients with lung adenocarcinoma (LUAD) but not in those with squamous cell carcinoma (LUSC).<br /><br />The study confirms previous findings that NSCLC tumors can be classified as hot or cold based on TME subtypes, which can help predict the efficacy of ICI therapy. This classification may have implications for personalizing therapy and improving treatment success. The study utilized a transcriptomic-based TME classification platform and cellular deconvolution analysis to gain valuable insights into the molecular and cellular players involved in ICI therapy efficacy.<br /><br />Overall, this research provides further evidence of the importance of tumor microenvironment and biomarkers in predicting patient response and survival to ICI therapy in NSCLC.

Asset Subtitle

Dhruv Bansal

Meta Tag

Speaker Dhruv Bansal

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

biomarkers

immune checkpoint inhibitor therapy

non-small cell lung cancer

NSCLC

RNA-seq technology

tumor microenvironment

ICI treatment outcomes

progression-free survival

CD8 T cell infiltration

transcriptomic-based TME classification